RxDoctor Payments Data

David Schmerler, DO

Neurology · Cincinnati, OHNPI 1760707574

Payments from drug & device makers

$161,838in general payments, 2019–2025

Across 468 payments — averaging $345.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$88K
  • Acorda Therapeutics, Inc$45K
  • Biohaven Pharmaceuticals, Inc.$6K
  • Sunovion Pharmaceuticals Inc.$5K
  • Lundbeck LLC$5K
  • Catalyst Pharmaceuticals, Inc.$4K
  • plus $9K from 45 others

What the payments were for

  • Consulting fees$1,9131%
  • Speaking & faculty fees$145,63990%
  • Travel & lodging$2,7492%
  • Food & beverage$11,4217%
  • Education$1160%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$161,838 in reported general payments places this provider in the 80th percentile of 702 neurology providers in Ohio.

See all neurology providers in Ohio

Medicare billing

Part B allowed, 2024
$877,625
Medicare patients
515
Services billed
46,251

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RytaryCarbidopa/Levodopa180$243,249
GocovriAmantadine Hcl28$114,062
NuplazidPimavanserin Tartrate14$75,531
UbrelvyUbrogepant23$32,415
Carbidopa-LevodopaCarbidopa/Levodopa764$31,848
Rasagiline Mesylate60$12,539
Memantine Hcl309$7,351
RivastigmineRivastigmine Tartrate125$5,752
Tetrabenazine12$5,605
Primidone186$4,341
Carbidopa-Levodopa ErCarbidopa/Levodopa140$3,853
Donepezil Hcl419$3,304
AmantadineAmantadine Hcl54$3,248
Selegiline Hcl17$2,397
Propranolol Hcl ErPropranolol Hcl42$2,214

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Amneal Pharmaceuticals LLCRytary$1,049$243,249180 claims
MDD US Operations, LLCGocovri$315$114,06228 claims
Acadia Pharmaceuticals IncNuplazid$173$75,53114 claims
AbbVieUbrelvy$87,834$32,41523 claims
Upsher-smith Laboratories LLCTopiramate$27$17932 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 702 neurology providers in Ohio.

Other neurology in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →